Predictors of long-term survival in patients with lung cancer included in the Randomized Spanish Lung Cancer Group 0008 Phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy

Clinical Lung Cancer

Volumn 10, Issue 3, 2009, Pages 180-186

  Garrido, Pilar ^a   Rosell, Rafael ^b   Massutí, Bartomeu ^c   Cardenal, Felipe ^d   Alberola, Vicente ^e   Dómine, Manuel ^f   Maeztu, Inmaculada ^g   Ramos, Alfredo ^a   Arellano, Antonio ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^d HOSPITAL DURAN I REYNALS   (Spain)

^e HOSPITAL ARNAU DE VILANOVA   (Spain)

^f Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^g HOSPITAL VIRGEN DE LOS LIRIOS   (Spain)

Author keywords

Clinical parameters; Hemoglobin; Performance status; Prognostic factors

Indexed keywords

CARBOPLATIN; DOCETAXEL; GEMCITABINE; HEMOGLOBIN; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; FORCED EXPIRATORY VOLUME; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERSTITIAL PNEUMONIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGNOSIS; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEX DIFFERENCE; THROMBOCYTOPENIA; TREATMENT RESPONSE; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; RETROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 67649413566     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2009.n.025     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non small cell lung cancer. J Clin Oncol 1999; 17:2692-9.
3. Curran W, Scott C, Langer C, et al. Long-term benefit is observed in a phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non small cell lung cancer: Radiation Therapy Oncology Group 9410. Proc Am Soc Clin Oncol 2003; 22:621 (Abstract 2499).
4. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. J Clin Oncol 2005; 23:5910-7.
5. Auperin A, Rolland E, Curran W, et al. Concomitant radio-chemotherapy versus sequential radio-chemotherapy in locally advanced non-small cell lung cancer: a meta-analysis using individual patient data from randomized clinical trials. J Thoracic Oncol 2007; 2:S310 (Abstract A1-05).
6. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology. Treatment of unresectable non small cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330-53.
7. Garrido P, Massutí B, Cardenal F, et al. Induction or consolidation chemotherapy with docetaxel and gemcitabine plus concomitant chemoradiotherapy with docetaxel and carboplatin for unresectable stage III non-small cell lung cancer patients. Initial report of the randomized phase II trial SLCG 0008. J Clin Oncol 2005; 23(16 suppl):652s (Abstract 7129).
8. Garrido P, Massutí T, Morán T, et al. Concomitant chemoradiation plus induction or consolidation chemotherapy with docetaxel and gemcitabine for unresectable stage III non-small cell lung cancer patients. Results of the randomized SLCG 0008 phase II trial. J Clin Oncol 2007; 25(18 suppl):414s (Abstract 7620).
9. Bayman NA, Blackhall F, Jain P, et al. Management of unresectable stage III non-small cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment. Clin Lung Cancer 2008; 9:92-101.
10. Sculier JP, Chansky K, Crowley JJ, et al. The impact of additional prognostic factors in survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposal for the 7th Edition. J Thorac Oncol 2008; 3:457-66.
11. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2:706-14. (Pubitemid 47357522)
12. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65:25-32.
13. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. J Clin Oncol 1995; 13:1221-30.
14. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9:1618-26.
15. Hoang T, Xu R, Schiller J, et al. Clinical model to predict survival in chemonaive patients with advanced non-small cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005; 23:175-83.
16. Mandrekar SJ, Schild SE, Hillman SL, et al. A prognostic model for advanced stage non-small cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer 2006; 107:781-92.
17. Paralkar VR, Li T, Langer CJ. Population characteristics and prognostic factors in metastatic non-small cell lung cancer: a Fox Chase Cancer Center retrospective. Clin Lung Cancer 2008; 9:116-21.
18. Firat S, Byhardt RW, Gore E. Comorbidity and Karnofsky performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002; 54:357-64.
19. Langer CJ, Hsu C, Curran WJ, et al. Elderly patients with locally advanced NSCLC benefit from combined modality therapy: secondary analysis of RTOG 9410. Proc Am Soc Clin Oncol 2002; 21:(Abstract 1193).
20. Langer CJ, Paulus R, Curran W, et al. Rethinking prognostic factors in the era of combined modality therapy for locally advanced non-small cell lung cancer (LANSCLC): a retrospective analysis of RTOG Protocols 9410 and 9801. J Thorac Oncol 2007; 2(suppl 8):S309 (Abstract A1-03).
21. Werner-Wasik M, Scott C, Cox J, et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group patients with locally advanced non-small cell lung cancer: identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000; 48:1475-82.
22. Bradley JD, Ieumwananonthachai N, Purdy JA, et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapies for non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys 2002; 52:49-57.
23. Werner-Wasik M, Swann RS, Bradley J, et al. Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation-escalation study in patients with inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2008; 70:385-90.
24. Basaki K, Abe Y, Aoki M, et al. Prognostic factors for survival in stage III nonsmall cell lung cancer treated with definitive radiation therapy: impact of tumor volume. Int J Radiat Oncol Biol Phys 2006; 64:449-54.
25. Dehing-Oberije C, De Ruysscher D, van der Weide H, et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo) radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70:1039-44.
26. Dehing-Oberije C, Yu S, De Ruysscher D, et al. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2008 Dec 16. [Epub ahead of print].
27. Kelly K, Gaspar LE, Chansky K, et al. Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. J Clin Oncol 2005; 23(16 suppl):634s (Abstract 7058).
28. Ademuyiwa FO, Johnson CS, White AS, et al. Prognostic factors in stage III nonsmall cell lung cancer. Clin Lung Cancer 2007; 8:478-82.
29. MacRae R, Shyr Y, Johnson D, et al. Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol 2002; 64:37-40.
30. Cox JD, Pajak TF, Asbell S, et al. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 1993; 27:493-8.
31. Machtay M, Hsu C, Komaki R, et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys 2005; 63:667-71.
32. Rosell R, Méndez P, Isla D, et al. Platinum resistance related to a functional NER pathway. J Thorac Oncol 2007; 2:1063-6.
33. Cobo M, Isla D, Massutí B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007; 25:2747-54.
34. Tarón M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004; 13:2443-9.
35. Kong FM, Ao X, Wang L, et al. The use of blood biomarkers to predict radiation lung toxicity: a potential strategy to individualize thoracic radiation therapy. Cancer Control 2008; 15:140-50.